Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells - PubMed (original) (raw)
Clinical Trial
. 1999 Mar;161(3):777-82.
Affiliations
- PMID: 10022683
Clinical Trial
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
L Höltl et al. J Urol. 1999 Mar.
Abstract
Purpose: Dendritic cells are the most potent stimulators of immune responses including antitumor responses. We performed a pilot study of cultured antigen loaded dendritic cells in patients with metastatic renal cell carcinoma.
Materials and methods: Dendritic cells were obtained by culturing plastic adherent mononuclear cells from peripheral blood for 5 days in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4. Day 5 dendritic cells were loaded with cell lysate from cultured autologous tumor cells and with the immunogenic protein keyhole-limpet hemocyanin (KLH) which serves as a helper antigen and as a tracer molecule. During the antigen pulse dendritic cells were activated with a combination of tumor necrosis factor-alpha and prostaglandin E2. Dendritic cells were administered by 3 intravenous infusions at monthly intervals. Cellular and humoral immune responses to KLH and cell lysate were measured in vitro before and after the vaccinations.
Results: Preparation of 12 dendritic cell vaccines from patients with advanced renal cell carcinoma was successful. Treatment with fully activated CD83+ dendritic cells was well tolerated with moderate fever as the only side effect. Potent immunological responses to KLH and, most importantly, against cell lysate could be measured in vitro after the vaccinations.
Conclusions: Our data demonstrate that a dendritic cell based vaccine can induce antigen specific immunity in patients with metastatic renal cell carcinoma. Dendritic cell based immunotherapy represents a feasible, well tolerated and promising new approach for the treatment of advanced renal cell carcinoma.
Similar articles
- [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC. Wang H, et al. Ai Zheng. 2006 May;25(5):625-30. Ai Zheng. 2006. PMID: 16687087 Chinese. - Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Mulders P, et al. Clin Cancer Res. 1999 Feb;5(2):445-54. Clin Cancer Res. 1999. PMID: 10037196 - Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Tso CL, et al. Cancer Res. 2001 Nov 1;61(21):7925-33. Cancer Res. 2001. PMID: 11691814 - Dendritic cell-based immunotherapy of renal cell carcinoma.
Thurnher M, Rieser C, Höltl L, Papesh C, Ramoner R, Bartsch G. Thurnher M, et al. Urol Int. 1998;61(2):67-71. doi: 10.1159/000030291. Urol Int. 1998. PMID: 10049189 Review. - [Immune anticancer response: recent advances in the treatment of renal cell carcinoma].
Bouet F, Catros V. Bouet F, et al. Ann Biol Clin (Paris). 2004 May-Jun;62(3):257-68. Ann Biol Clin (Paris). 2004. PMID: 15217758 Review. French.
Cited by
- Deciphering Human Leukocyte Antigen Susceptibility Maps From Immunopeptidomics Characterization in Oncology and Infections.
Juanes-Velasco P, Landeira-Viñuela A, Acebes-Fernandez V, Hernández ÁP, Garcia-Vaquero ML, Arias-Hidalgo C, Bareke H, Montalvillo E, Gongora R, Fuentes M. Juanes-Velasco P, et al. Front Cell Infect Microbiol. 2021 May 28;11:642583. doi: 10.3389/fcimb.2021.642583. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34123866 Free PMC article. Review. - Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.
Acebes-Fernández V, Landeria-Viñuela A, Juanes-Velasco P, Hernández AP, Otazo-Perez A, Manzano-Román R, Gongora R, Fuentes M. Acebes-Fernández V, et al. Nanomaterials (Basel). 2020 Jun 29;10(7):1274. doi: 10.3390/nano10071274. Nanomaterials (Basel). 2020. PMID: 32610601 Free PMC article. Review. - Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.
Zhang H, Wang Y, Wang QT, Sun SN, Li SY, Shang H, He YW. Zhang H, et al. Front Cell Dev Biol. 2020 Mar 27;8:205. doi: 10.3389/fcell.2020.00205. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32292785 Free PMC article. - Novel approaches for the design, delivery and administration of vaccine technologies.
Wallis J, Shenton DP, Carlisle RC. Wallis J, et al. Clin Exp Immunol. 2019 May;196(2):189-204. doi: 10.1111/cei.13287. Epub 2019 Apr 8. Clin Exp Immunol. 2019. PMID: 30963549 Free PMC article. Review. - Immunotherapy of hepatocellular carcinoma.
Sangro B, Palmer D, Melero I. Sangro B, et al. Hepat Oncol. 2014 Oct;1(4):433-446. doi: 10.2217/hep.14.16. Epub 2014 Dec 11. Hepat Oncol. 2014. PMID: 30190978 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical